Biocept Saham

Biocept Margin OCF

Delisted

Margin Arus Kas Operasional dari Biocept (BIOC) pada 5 Agu 2026 adalah -51,39 %. Tahun sebelumnya, Margin Arus Kas Operasional adalah 6,02 % — perubahan sebesar -953,04% (lebih rendah).

Margin OCF

-51,39 %

YoY

-953,04%

Terakhir Diperbarui:

Margin Arus Kas Operasional dari Biocept adalah 2026 -51,39 % . Margin Arus Kas Operasional dari Biocept adalah 2025 6,02 % . Menurun -953,04% lebih rendah dibandingkan dengan tahun sebelumnya.
Access this data via the Eulerpool API

Biocept Analisis saham

Apa yang dilakukan Biocept? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept adalah salah satu perusahaan paling populer di Eulerpool.

Pertanyaan yang Sering Diajukan tentang saham Biocept

Margin Arus Kas Operasional Biocept adalah -51,39 % pada tahun 2026.

Margin Arus Kas Operasional dari Biocept berubah dari 6,02 % menjadi -51,39 %, mewakili perubahan -953,04%. Nilainya lebih rendah daripada tahun sebelumnya.

Di Eulerpool Anda dapat menemukan perkembangan historis lengkap Margin Arus Kas Operasional Biocept sejak 2006 – dengan nilai tahunan, bagan, dan analisis detail.

Margin OCF mengukur persentase pendapatan yang dikonversi menjadi arus kas operasional. Ini menunjukkan efisiensi generasi kas dari operasi bisnis inti.

Nilai '' yang 'baik' bervariasi menurut industri dan tahap perusahaan. Di Eulerpool, Anda dapat membandingkan Biocept Margin Arus Kas Operasional dengan pesaing sektor dan rata-rata industri untuk menilai apakah menarik.

Untuk mengevaluasi Margin Arus Kas Operasional, sangat penting untuk membandingkannya dengan perusahaan sejenis di industri dan sektor yang sama. Di Eulerpool, Anda dapat menemukan perbandingan industri langsung untuk Margin Arus Kas Operasional.

Access this data via the Eulerpool API

Margin — Biocept

Semua Metrik Kunci — Biocept